Akebia Therapeutics Inc., of Cambridge, Mass., said it completed enrollment in its ongoing 200-patient phase IIb study of AKB-6548, a hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of anemia associated with chronic kidney disease in patients who are not dependent on dialysis.